Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma

Paolo Corradini, Michele Cavo, Henk Lokhorst, Giovanni Martinelli, Carolina Terragna, Ignazio Majolino, Pinuccia Valagussa, Mario Boccadoro, Diana Samson, Andrea Bacigalupo, Nigel Russell, Vittorio Montefusco, Claudia Voena, Gosta Gahrton

Research output: Contribution to journalArticle

Abstract

Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive value of molecular monitoring. Using polymerase chain reaction (PCR) for immunoglobulin gene rearrangements it was possible to generate a clone-specific molecular marker in 48 of 70 patients. Of these 48 patients, 16 (33%) attained durable PCR-negativity after transplantation, whereas 13 (27%) remained persistently PCR-positive and 19 (40%) showed a mixed pattern. The cumulative risk of relapse at 5 years was 0% for PCR-negative patients, 33% for PCR-mixed patients, and 100% for PCR-positive patients. Within the group studied it was not possible to identify any clinical feature predictive of durable PCR-negativity. We believe that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival.

Original languageEnglish
Pages (from-to)1927-1929
Number of pages3
JournalBlood
Volume102
Issue number5
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

Polymerase chain reaction
Stem Cell Transplantation
Stem cells
Multiple Myeloma
Recurrence
Polymerase Chain Reaction
Survival
Immunoglobulin Genes
Gene Rearrangement
Longitudinal Studies
Immunoglobulins
Clone Cells
Genes
Transplantation
Prospective Studies
Monitoring

ASJC Scopus subject areas

  • Hematology

Cite this

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. / Corradini, Paolo; Cavo, Michele; Lokhorst, Henk; Martinelli, Giovanni; Terragna, Carolina; Majolino, Ignazio; Valagussa, Pinuccia; Boccadoro, Mario; Samson, Diana; Bacigalupo, Andrea; Russell, Nigel; Montefusco, Vittorio; Voena, Claudia; Gahrton, Gosta.

In: Blood, Vol. 102, No. 5, 01.09.2003, p. 1927-1929.

Research output: Contribution to journalArticle

Corradini, P, Cavo, M, Lokhorst, H, Martinelli, G, Terragna, C, Majolino, I, Valagussa, P, Boccadoro, M, Samson, D, Bacigalupo, A, Russell, N, Montefusco, V, Voena, C & Gahrton, G 2003, 'Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma', Blood, vol. 102, no. 5, pp. 1927-1929. https://doi.org/10.1182/blood-2003-01-0189
Corradini, Paolo ; Cavo, Michele ; Lokhorst, Henk ; Martinelli, Giovanni ; Terragna, Carolina ; Majolino, Ignazio ; Valagussa, Pinuccia ; Boccadoro, Mario ; Samson, Diana ; Bacigalupo, Andrea ; Russell, Nigel ; Montefusco, Vittorio ; Voena, Claudia ; Gahrton, Gosta. / Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. In: Blood. 2003 ; Vol. 102, No. 5. pp. 1927-1929.
@article{2132e6fb047445ed828639dac60fcbc7,
title = "Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma",
abstract = "Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive value of molecular monitoring. Using polymerase chain reaction (PCR) for immunoglobulin gene rearrangements it was possible to generate a clone-specific molecular marker in 48 of 70 patients. Of these 48 patients, 16 (33{\%}) attained durable PCR-negativity after transplantation, whereas 13 (27{\%}) remained persistently PCR-positive and 19 (40{\%}) showed a mixed pattern. The cumulative risk of relapse at 5 years was 0{\%} for PCR-negative patients, 33{\%} for PCR-mixed patients, and 100{\%} for PCR-positive patients. Within the group studied it was not possible to identify any clinical feature predictive of durable PCR-negativity. We believe that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival.",
author = "Paolo Corradini and Michele Cavo and Henk Lokhorst and Giovanni Martinelli and Carolina Terragna and Ignazio Majolino and Pinuccia Valagussa and Mario Boccadoro and Diana Samson and Andrea Bacigalupo and Nigel Russell and Vittorio Montefusco and Claudia Voena and Gosta Gahrton",
year = "2003",
month = "9",
day = "1",
doi = "10.1182/blood-2003-01-0189",
language = "English",
volume = "102",
pages = "1927--1929",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma

AU - Corradini, Paolo

AU - Cavo, Michele

AU - Lokhorst, Henk

AU - Martinelli, Giovanni

AU - Terragna, Carolina

AU - Majolino, Ignazio

AU - Valagussa, Pinuccia

AU - Boccadoro, Mario

AU - Samson, Diana

AU - Bacigalupo, Andrea

AU - Russell, Nigel

AU - Montefusco, Vittorio

AU - Voena, Claudia

AU - Gahrton, Gosta

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive value of molecular monitoring. Using polymerase chain reaction (PCR) for immunoglobulin gene rearrangements it was possible to generate a clone-specific molecular marker in 48 of 70 patients. Of these 48 patients, 16 (33%) attained durable PCR-negativity after transplantation, whereas 13 (27%) remained persistently PCR-positive and 19 (40%) showed a mixed pattern. The cumulative risk of relapse at 5 years was 0% for PCR-negative patients, 33% for PCR-mixed patients, and 100% for PCR-positive patients. Within the group studied it was not possible to identify any clinical feature predictive of durable PCR-negativity. We believe that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival.

AB - Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive value of molecular monitoring. Using polymerase chain reaction (PCR) for immunoglobulin gene rearrangements it was possible to generate a clone-specific molecular marker in 48 of 70 patients. Of these 48 patients, 16 (33%) attained durable PCR-negativity after transplantation, whereas 13 (27%) remained persistently PCR-positive and 19 (40%) showed a mixed pattern. The cumulative risk of relapse at 5 years was 0% for PCR-negative patients, 33% for PCR-mixed patients, and 100% for PCR-positive patients. Within the group studied it was not possible to identify any clinical feature predictive of durable PCR-negativity. We believe that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival.

UR - http://www.scopus.com/inward/record.url?scp=0041438792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041438792&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-01-0189

DO - 10.1182/blood-2003-01-0189

M3 - Article

C2 - 12738666

AN - SCOPUS:0041438792

VL - 102

SP - 1927

EP - 1929

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -